Immutep Limited

IMM

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Perennial Better Future Fund (Managed Fund)

IMPQ

IMPQ.AX was created on 2021-09-29 by Perennial. The fund's investment portfolio concentrates primarily on total market equity. The objective of the Fund is to deliver long-term capital growth predominately through investments in Australian and New Zealand listed smaller and mid-cap companies that are Better Future Investments.

Imexhs Limited

IME

ImExHS Ltd. engages in the development and sale of its Hiruko software platform. The company is headquartered in Mascot, New South Wales and currently employs 400 full-time employees. The company went IPO on 2005-12-14. The firm develops software-as-a-service imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are cloud-based, vendor neutral and zero footprint, with no need for installed software. Its radiology services provide radiological diagnostic services to hospitals and medical facilities in Colombia and Spain using IMEXHS medical imaging software. The firm's services business also provides it with medical images and radiologists interpretation and reports to develop artificial intelligence (AI) tools. Its solutions include AQUILA - Radiology, ALULA - Pathology, ANTEROS - cardiology, artificial intelligence and advanced visualization.

Infinity Mining Limited

IMI

Infinity Mining Ltd. engages in the exploration and development of gold, copper, base metals and lithium mineral properties. These tenements are located in highly prospective Lithium, Nickel, Copper and Gold terranes. The firm's is focused on substantial East Pilbara lithium assets. The Pilbara project tenements comprise an extensive portfolio of Lithium, Gold, Nickel, Copper and Zinc exploration tenements located in the Pilbara region of northwest Western Australia, including the Tambourah South, Tambourah North, Strelley Gorge, Hillside and Panorama Projects. The Tambourah South Project is located 80 kilometers (km) southwest of Marble Bar and 155 km south of Port Headland. The Panorama Project encompasses three tenements and is prospective for a range of target types. The Central Goldfields region is host to deposits of gold, base metals and nickel hosted within greenstone belts and granite intrusives.